GleamWall
中文EN

NCNA NuCana plc IFRS

Pharmaceutical Preparations · Nasdaq · SEC CIK 1709626 · Reporting currency GBP · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY—
TTM net income YoY-54.5%
TTM EPS YoY100.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-193.9%
ROA-131.6%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets18.5%
Debt / equity0.00x
Current ratio5.60x
Interest coverage-1.59x

Cash quality & payout

Operating cash flow / net income0.25x
Accruals ratio-98.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Unit: GBP FY2025*2025-12-31FY2024*2024-12-31
Income statement
Revenue——
R&D expense12.74M18.02M
Operating income-20.11M-22.81M
Interest expense12.65M0
Pretax income-30.52M-22.45M
Income tax-1.17M-3.45M
Net income-29.35M-19.00M
EBITDA-19.84M-22.29M
EPS (basic)0.00-0.26
EPS (diluted)0.00-0.26
Balance sheet
Cash & equivalents24.25M6.75M
Receivables849,000922,000
Current assets26.86M12.27M
PP&E, netmay include right-of-use assets (IFRS)658,000197,000
Intangibles2.20M2.20M
Total assets29.83M14.77M
Current liabilities4.79M8.67M
Total liabilities5.51M8.82M
Shareholders' equity24.33M5.95M
Cash flow statement
Operating cash flow-7.47M-19.12M
Capital expenditure04,000
Free cash flow-7.47M-19.12M
Investing cash flow159,00079,000
Financing cash flow25.01M8.18M
Depreciation & amortization274,000522,000
Stock-based compensation10.03M1.65M

Free plan shows the latest 2 periods; Pro shows all 11 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company does not report gross profit in XBRL.

· Amounts are in the company's reporting currency, GBP, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.